U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 04:01 pm EDT
Share
U.S. NeuroSurgical Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 1.1 million compared to USD 0.617 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.08 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to USD 0.08 a year ago.
For the six months, net loss was USD 1.52 million compared to USD 0.325 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.19 compared to USD 0.04 a year ago.
U.S. NeuroSurgical Holdings, Inc., through its wholly-owned subsidiaries, holds interests in radiological treatment facilities. The Company owns and operates stereotactic radiosurgery centers, utilizing gamma knife technology. It owns, or holds interests in, the gamma knife and radiation treatment centers, and charges the hospital or medical facility, where the unit is housed and maintained, based on utilization. It is also focused on developing cancer centers featuring radiation therapy. These centers utilize linear accelerators with Intensity Modulated Radiation Therapy and Image Guided Radiation Therapy capabilities. It is focused on launching and development of Medicare advantage plans for seniors by its subsidiaries, Elite Health Plan and Elite Health Plan of Nevada, Inc. Medicare is the federal health insurance program for people ages 65 and over, to cover people under 65 with certain disabilities and people with end-stage renal disease requiring dialysis or kidney transplant.